Molecular pathogenesis and prognostication of "low‐grade'' and "high‐grade" endometrial stromal sarcoma. Issue 3 (10th November 2020)

• Record Type: Journal Article
• Authors: Micci, Francesca; Heim, Sverre; Panagopoulos, Ioannis
• Is Part Of: Genes, chromosomes & cancer. Volume 60:Issue 3(2021)
• Page Start: 160
• Page End: 167
• Publication Date: 2020-11-10
• Subjects: chromosomal aberrations -- endometrial stromal sarcoma -- fusion gene -- high‐grade ESS -- low‐grade ESS; Cancer -- Genetic aspects -- Periodicals; 616.994042
• DOI: 10.1002/gcc.22907
• Languages: English
• ISSNs: 1045-2257

Abstract

Abstract: Endometrial stromal sarcomas (ESS) are a heterogeneous group of rare mesenchymal cancers. Considerable knowledge has been gained in recent years about the molecular characteristics of these cancers, which helps to classify them in a more meaningful manner leading to improved diagnosis, prognostication, and treatment. According to this classification, ESS is now grouped as low‐ or high‐grade. ESS may have overlapping clinical presentation, morphology, and immunohistochemical profile. Their genetic characteristics allow subdivision of many of them depending on which pathogenetically important fusion genes they carry, but clearly much more needs to be unraveled in this regard. We here provide an overview of the molecular pathogenetic knowledge gained so far on low‐ and high‐grade ESS.